Variables predicting clinical remission among adults with severe asthma treated with biologic agents
Conclusions. Omalizumab and mepolizumab provide significant clinical remission rates in severe asthma. FEV1% predicted is a variable that can independently predict clinical remission among severe asthmatics receiving biologic agents.PMID:38054608 | DOI:10.23822/EurAnnACI.1764-1489.318 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: S Ye şilkaya K Aksu G Tu ğçe Vural Solak O Akkale O Telli H C Tu ğlu G K öycü Buhari S N Bah çecioğlu S Demir Source Type: research

Delayed postoperative reactions to metamizole: a diagnostic challenge
Conclusions. This study demonstrated that for a correct diagnosis a high degree of suspicion about possible delayed hypersensitivity drug reactions to metamizole in the postoperative setting is needed. In the investigation, provocation test with metamizole was decisive for diagnostic confirmation.PMID:38054601 | DOI:10.23822/EurAnnACI.1764-1489.317 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: A Lopes M Paulino A Sp ínola Santos E Pedro M Branco Ferreira Source Type: research

Probiotics, prebiotics and food allergy
Conclusions. The potential of probiotics to be used as therapeutic adjuvants in CMA and peanut OI is promising. However, there is inconsistency regarding the type of probiotic, the dose and duration of supplementation. Further studies are needed to clarify the role of probiotics and prebiotics in FA.PMID:38054607 | DOI:10.23822/EurAnnACI.1764-1489.319 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: J F Ribeiro C Pedrosa Source Type: research

Variables predicting clinical remission among adults with severe asthma treated with biologic agents
Conclusions. Omalizumab and mepolizumab provide significant clinical remission rates in severe asthma. FEV1% predicted is a variable that can independently predict clinical remission among severe asthmatics receiving biologic agents.PMID:38054608 | DOI:10.23822/EurAnnACI.1764-1489.318 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: S Ye şilkaya K Aksu G Tu ğçe Vural Solak O Akkale O Telli H C Tu ğlu G K öycü Buhari S N Bah çecioğlu S Demir Source Type: research

Delayed postoperative reactions to metamizole: a diagnostic challenge
Conclusions. This study demonstrated that for a correct diagnosis a high degree of suspicion about possible delayed hypersensitivity drug reactions to metamizole in the postoperative setting is needed. In the investigation, provocation test with metamizole was decisive for diagnostic confirmation.PMID:38054601 | DOI:10.23822/EurAnnACI.1764-1489.317 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: A Lopes M Paulino A Sp ínola Santos E Pedro M Branco Ferreira Source Type: research

Probiotics, prebiotics and food allergy
Conclusions. The potential of probiotics to be used as therapeutic adjuvants in CMA and peanut OI is promising. However, there is inconsistency regarding the type of probiotic, the dose and duration of supplementation. Further studies are needed to clarify the role of probiotics and prebiotics in FA.PMID:38054607 | DOI:10.23822/EurAnnACI.1764-1489.319 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: J F Ribeiro C Pedrosa Source Type: research

Variables predicting clinical remission among adults with severe asthma treated with biologic agents
Conclusions. Omalizumab and mepolizumab provide significant clinical remission rates in severe asthma. FEV1% predicted is a variable that can independently predict clinical remission among severe asthmatics receiving biologic agents.PMID:38054608 | DOI:10.23822/EurAnnACI.1764-1489.318 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: S Ye şilkaya K Aksu G Tu ğçe Vural Solak O Akkale O Telli H C Tu ğlu G K öycü Buhari S N Bah çecioğlu S Demir Source Type: research

Delayed postoperative reactions to metamizole: a diagnostic challenge
Conclusions. This study demonstrated that for a correct diagnosis a high degree of suspicion about possible delayed hypersensitivity drug reactions to metamizole in the postoperative setting is needed. In the investigation, provocation test with metamizole was decisive for diagnostic confirmation.PMID:38054601 | DOI:10.23822/EurAnnACI.1764-1489.317 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: A Lopes M Paulino A Sp ínola Santos E Pedro M Branco Ferreira Source Type: research

Probiotics, prebiotics and food allergy
Conclusions. The potential of probiotics to be used as therapeutic adjuvants in CMA and peanut OI is promising. However, there is inconsistency regarding the type of probiotic, the dose and duration of supplementation. Further studies are needed to clarify the role of probiotics and prebiotics in FA.PMID:38054607 | DOI:10.23822/EurAnnACI.1764-1489.319 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: J F Ribeiro C Pedrosa Source Type: research

Variables predicting clinical remission among adults with severe asthma treated with biologic agents
Conclusions. Omalizumab and mepolizumab provide significant clinical remission rates in severe asthma. FEV1% predicted is a variable that can independently predict clinical remission among severe asthmatics receiving biologic agents.PMID:38054608 | DOI:10.23822/EurAnnACI.1764-1489.318 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: S Ye şilkaya K Aksu G Tu ğçe Vural Solak O Akkale O Telli H C Tu ğlu G K öycü Buhari S N Bah çecioğlu S Demir Source Type: research

Delayed postoperative reactions to metamizole: a diagnostic challenge
Conclusions. This study demonstrated that for a correct diagnosis a high degree of suspicion about possible delayed hypersensitivity drug reactions to metamizole in the postoperative setting is needed. In the investigation, provocation test with metamizole was decisive for diagnostic confirmation.PMID:38054601 | DOI:10.23822/EurAnnACI.1764-1489.317 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: A Lopes M Paulino A Sp ínola Santos E Pedro M Branco Ferreira Source Type: research

Probiotics, prebiotics and food allergy
Conclusions. The potential of probiotics to be used as therapeutic adjuvants in CMA and peanut OI is promising. However, there is inconsistency regarding the type of probiotic, the dose and duration of supplementation. Further studies are needed to clarify the role of probiotics and prebiotics in FA.PMID:38054607 | DOI:10.23822/EurAnnACI.1764-1489.319 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: J F Ribeiro C Pedrosa Source Type: research

Variables predicting clinical remission among adults with severe asthma treated with biologic agents
Conclusions. Omalizumab and mepolizumab provide significant clinical remission rates in severe asthma. FEV1% predicted is a variable that can independently predict clinical remission among severe asthmatics receiving biologic agents.PMID:38054608 | DOI:10.23822/EurAnnACI.1764-1489.318 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - December 6, 2023 Category: Allergy & Immunology Authors: S Ye şilkaya K Aksu G Tu ğçe Vural Solak O Akkale O Telli H C Tu ğlu G K öycü Buhari S N Bah çecioğlu S Demir Source Type: research

IgE-mediated reactivity to non-specific lipid transfer protein (nsLTP): clinical implications and management ‒ consensus document of the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO)
Eur Ann Allergy Clin Immunol. 2023 Oct 20. doi: 10.23822/EurAnnACI.1764-1489.316. Online ahead of print.ABSTRACTThe primary cause of adult-onset food allergy in Mediterranean countries is IgE-mediated reactivity to non-specific Lipid Transfer Protein (nsLTP), with a prevalence of 9.5% in Italy. nsLTP is heat- and pepsin-stable due to its 3D structure, causing severe allergic reactions, even anaphylaxis. It's conserved across plants and a "panallergen" due to homologous forms in various vegetable foods. Found in Rosaceae fruits' skin, it's categorized into nsLTP1 (9 kDa) and nsLTP2 (7 kDa), representing 93% and 7% of the mo...
Source: European Annals of Allergy and Clinical Immunology - October 20, 2023 Category: Allergy & Immunology Authors: R Asero V Pravettoni D Villalta L Cecchi E Scala Source Type: research